Featured Research

from universities, journals, and other organizations

Reference pricing for proton therapy will help establish clinical benefits

Date:
April 21, 2014
Source:
Perelman School of Medicine at the University of Pennsylvania
Summary:
"Reference pricing” for proton therapy has been proposed by researchers. This is a relatively new model that establishes a standard price for different therapies with similar outcomes. Proton therapy is in the proverbial chicken or the egg scenario. Companies are pulling back on reimbursements to treat some cancers—notably prostate, breast and lung—because of the added expense and limited evidence to back it up. But in order to demonstrate the technology’s clinical benefit—which is showing promise as a more effective and better tolerated radiation—more studies with patients are needed.

Proton therapy is in the proverbial chicken or the egg scenario. Companies are pulling back on reimbursements to treat some cancers -- notably prostate, breast and lung -- because of the added expense and limited evidence to back it up. But in order to demonstrate the technology's clinical benefit -- which is showing promise as a more effective and better tolerated radiation -- more studies with patients are needed. So which should come first?

Both, say Abramson Cancer Center physicians Justin E. Bekelman, MD, an assistant professor of Radiation Oncology at the Perelman School of Medicine at the University of Pennsylvania, and Stephen M. Hahn, MD, chair of Radiation Oncology. In an article published today in the Journal of Clinical Oncology, the authors propose "reference pricing" -- a relatively new model that establishes a standard price for different therapies with similar outcomes. It would expand the patient base because of increased, cheaper coverage and thus research to establish whether its novel advantages translate into clinical benefits.

In this case, proton therapy should be set at the less expensive rate currently paid for intensity-modulated radiation therapy (IMRT), which is covered under most insurance plans, and Medicare and Medicaid, the authors propose.

Having found success with this model with private insurers since it was implemented in 2010, the University of Pennsylvania Health System is leading the way for other centers -- which are popping up around the country -- to make other treatments options more accessible to patients while moving the field along even further.

"We want to be a responsible leader for both patients and payers," said Bekelman. "This proposal does just that. This is an important and promising therapy for patients. We need to generate evidence to see whether proton therapy is better or equivalent to other modalities."

Next month, the Health Technology Assessment Program (HTAP) in Washington state will decide whether and under what circumstances the state's public payers will pay for proton therapy -- a decision that could have powerful influence over payment policies of other payers in the U.S. health care system. The HTAP has a unique legislative mandate in the U.S. to evaluate health technologies and translate evidence of comparative and cost effectiveness into payment policy.

This examination of proton therapy comes at decisive moment, as major insurers have recently announced policies that restrict coverage for proton therapy for certain cancers.

"HTAP should not follow suit," said Bekelman. "We propose a better way forward with reference pricing. By linking payment for proton therapy to evidence development, we echo prior calls to tie reimbursement for unproven technologies to the broad mandate of comparative effectiveness research with randomized trials."

When compared to conventional radiation therapies, proton therapy stands to offer several benefits for patients who are candidates, including decreased radiation to normal tissues, decreased side effects and complications, and the ability to re-treat tumors after recurrences. Every day, over 100 patients are treated at Penn Medicine's Roberts Proton Therapy Center. Several studies have shown such advantages, but what's lacking is randomized clinical trials.

Moving forward, the authors call for the HTAP to lead the way by deciding on behalf of its public payers to cover proton therapy under a policy of reference pricing with evidence development. They also call for a national proton therapy clinical trials consortium, led by physicians, and comprised of patients, payers, federal agencies, and device manufacturers, to jump start, design and fund research-related costs for high-quality multi-center comparative effectiveness studies.

"The tradeoff is justifiable," the authors write. "We will have reduced reimbursement, at least for a time, to promote evidence generation for a technology that or may not lead to better outcomes for great number of patients."

"This will preserve access to the technology and renew efforts to conduct crucial research," they add.


Story Source:

The above story is based on materials provided by Perelman School of Medicine at the University of Pennsylvania. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. E. Bekelman, S. M. Hahn. Reference Pricing With Evidence Development: A Way Forward for Proton Therapy. Journal of Clinical Oncology, 2014; DOI: 10.1200/JCO.2014.55.6613

Cite This Page:

Perelman School of Medicine at the University of Pennsylvania. "Reference pricing for proton therapy will help establish clinical benefits." ScienceDaily. ScienceDaily, 21 April 2014. <www.sciencedaily.com/releases/2014/04/140421164144.htm>.
Perelman School of Medicine at the University of Pennsylvania. (2014, April 21). Reference pricing for proton therapy will help establish clinical benefits. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2014/04/140421164144.htm
Perelman School of Medicine at the University of Pennsylvania. "Reference pricing for proton therapy will help establish clinical benefits." ScienceDaily. www.sciencedaily.com/releases/2014/04/140421164144.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins